Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review.
Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review.
Scoping review of randomized controlled trials finds limited high-quality evidence for medicinal cannabis in mental health and substance use disorders.
This scoping review systematically maps the current landscape of rigorous trial evidence for cannabis in psychiatric conditions. The authors’ characterization of evidence as ‘controversial and under-explored’ with previous reviews finding ‘inconclusive evidence due to heterogeneity’ indicates the field lacks the robust, consistent findings needed for evidence-based recommendations.
Mental health conditions represent a major area of patient interest in medicinal cannabis, yet clinical guidance remains limited by study quality and design inconsistencies. This review provides a structured assessment of what high-quality trial evidence actually exists, helping clinicians distinguish between patient enthusiasm and clinical evidence.
| Study Type | Scoping Review of Randomized Controlled Trials |
| Population | Human participants with mental health and substance use disorders as defined by DSM-5 |
| Intervention | Medicinal cannabis preparations |
| Comparator | Various controls (placebo, standard care, or other comparators) |
| Primary Outcome | Efficacy and safety of medicinal cannabis for mental health conditions |
| Key Finding | Evidence characterized as controversial and under-explored with inconclusive findings due to study heterogeneity |
| Journal | Clinical Drug Investigation |
| Year | 2024 |
The highest-quality randomized controlled trial evidence for medicinal cannabis in mental health and substance use disorders remains insufficient to support routine clinical recommendations. The field requires more rigorous, standardized trial designs before evidence-based treatment protocols can be established.
This abstract does not provide specific efficacy data, safety profiles, or detailed findings from individual trials. Without access to the full methodology and results, we cannot assess which specific mental health conditions showed promise or which cannabis formulations were studied.
Scoping reviews map existing literature but do not perform quality assessment or meta-analysis of pooled effects. The acknowledged heterogeneity in study designs limits the ability to draw definitive clinical conclusions, and publication bias may favor positive or novel findings in this emerging field.
While medicinal cannabis prescribing is increasing globally, the randomized controlled trial evidence for mental health applications remains preliminary and heterogeneous. Clinicians should approach these applications with appropriate caution, acknowledging both patient interest and the current limitations of our evidence base.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Is there strong evidence supporting medicinal cannabis for mental health conditions?
Current randomized controlled trial evidence for medicinal cannabis in treating mental health and substance use disorders is limited and of variable quality. This scoping review found insufficient high-quality evidence to definitively support its efficacy for DSM-5 classified mental health conditions, highlighting the need for more rigorous clinical trials.
What makes the research on cannabis for mental health so inconclusive?
Previous reviews have found inconclusive evidence primarily due to significant heterogeneity in study design, methodology, and quality across trials. The emerging nature of this field and varying regulatory frameworks have contributed to inconsistent research approaches and mixed findings.
How does the evidence for mental health differ from other medical conditions?
While some emerging evidence supports medicinal cannabis use for conditions like multiple sclerosis and epilepsy, its efficacy and safety profile for mental health conditions remains controversial and under-explored. The evidence base for psychiatric applications is significantly less established compared to certain neurological conditions.
Should clinicians prescribe medicinal cannabis for psychiatric patients?
Given the limited high-quality RCT evidence and controversial safety profile, clinicians should exercise caution when considering medicinal cannabis for mental health conditions. Any prescribing decisions should be based on careful risk-benefit analysis and consideration of established treatment alternatives with stronger evidence bases.
What are the main safety concerns with medicinal cannabis in mental health treatment?
The safety and tolerability profile of medicinal cannabis for mental health conditions remains inadequately characterized due to limited high-quality trial data. Potential concerns include psychiatric symptom exacerbation, dependency risks, and drug interactions, though comprehensive safety data from rigorous trials is still lacking.
